123 related articles for article (PubMed ID: 37726528)
21. Multi-pronged proteomic analysis to study the glioma pathobiology using cerebrospinal fluid samples.
Gahoi N; Malhotra D; Moiyadi A; Varma SG; Gandhi MN; Srivastava S
Proteomics Clin Appl; 2018 May; 12(3):e1700056. PubMed ID: 28679024
[TBL] [Abstract][Full Text] [Related]
22. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
23. Tissue Thiol Concentration in High-Grade Gliomas: Is There any Association Between IDH1 Mutation Presence and Tumoral Cellular Antioxidant Defense?
Evran S; Kayhan A; Baran O; Cevik S; Katar S; Kaya M; Sonmez D; Serin H; Hanimoglu H; Kaynar MY
Turk Neurosurg; 2021; 31(2):282-289. PubMed ID: 33575999
[TBL] [Abstract][Full Text] [Related]
24. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
[TBL] [Abstract][Full Text] [Related]
25. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry.
Schwartz SA; Weil RJ; Thompson RC; Shyr Y; Moore JH; Toms SA; Johnson MD; Caprioli RM
Cancer Res; 2005 Sep; 65(17):7674-81. PubMed ID: 16140934
[TBL] [Abstract][Full Text] [Related]
26. Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.
Pirlog R; Susman S; Iuga CA; Florian SI
Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31357616
[TBL] [Abstract][Full Text] [Related]
27. Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.
Lu BY; Gupta R; Aguirre-Ducler A; Gianino N; Wyatt H; Ribeiro M; Chiang VL; Contessa JN; Adeniran AJ; Jilaveanu LB; Kluger HM; Schalper KA; Goldberg SB
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34670827
[TBL] [Abstract][Full Text] [Related]
28. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
[TBL] [Abstract][Full Text] [Related]
29. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y
J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094
[TBL] [Abstract][Full Text] [Related]
30. [IDH1/2 mutations in gliomas].
Nobusawa S; Yokoo H
Brain Nerve; 2011 Dec; 63(12):1378-86. PubMed ID: 22147457
[TBL] [Abstract][Full Text] [Related]
31. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
32. Differential Proteome Profiling Analysis under Pesticide Stress by the Use of a Nano-UHPLC-MS/MS Untargeted Proteomic-Based Approach on a 3D-Developed Neurospheroid Model: Identification of Protein Interactions, Prognostic Biomarkers, and Potential Therapeutic Targets in Human IDH Mutant High-Grade Gliomas.
Louati K; Maalej A; Kolsi F; Kallel R; Gdoura Y; Borni M; Hakim LS; Zribi R; Choura S; Sayadi S; Chamkha M; Mnif B; Khemakhem Z; Boudawara TS; Boudawara MZ; Safta F
J Proteome Res; 2023 Nov; 22(11):3534-3558. PubMed ID: 37651309
[TBL] [Abstract][Full Text] [Related]
33. The advanced development of Cx43 and GAP-43 mediated intercellular networking in IDH1 wildtype diffuse and anaplastic gliomas with lower mitotic rate.
Krigers A; Moser P; Fritsch H; Demetz M; Brawanski K; Thomé C; Freyschlag CF
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3003-3009. PubMed ID: 34173871
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W
BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598
[TBL] [Abstract][Full Text] [Related]
36. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
[TBL] [Abstract][Full Text] [Related]
37. A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.
Wirthschaft P; Bode J; Simon AEM; Hoffmann E; van Laack R; Krüwel T; Dietrich F; Bucher D; Hahn A; Sahm F; Breckwoldt MO; Kurz FT; Hielscher T; Fischer B; Dross N; Ruiz de Almodovar C; von Deimling A; Herold-Mende C; Plass C; Boulant S; Wiestler B; Reifenberger G; Lichter P; Wick W; Tews B
Int J Cancer; 2018 Sep; 143(5):1176-1187. PubMed ID: 29582423
[TBL] [Abstract][Full Text] [Related]
38. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H
Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205
[TBL] [Abstract][Full Text] [Related]
39. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
40. [OMICS and biomarkers of glial tumors].
Idbaih A
Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]